Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

604 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.
Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. Jardim DL, et al. Among authors: subbiah v. Oncotarget. 2014 Apr 15;5(7):1837-45. doi: 10.18632/oncotarget.1828. Oncotarget. 2014. PMID: 24742823 Free PMC article. Clinical Trial.
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.
Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. Jardim DL, et al. Among authors: subbiah v. Clin Genitourin Cancer. 2015 Feb;13(1):e19-26. doi: 10.1016/j.clgc.2014.06.017. Epub 2014 Jul 3. Clin Genitourin Cancer. 2015. PMID: 25087088 Free PMC article.
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
Subbiah V, Berry J, Roxas M, Guha-Thakurta N, Subbiah IM, Ali SM, McMahon C, Miller V, Cascone T, Pai S, Tang Z, Heymach JV. Subbiah V, et al. Among authors: subbiah im. Lung Cancer. 2015 Jul;89(1):76-9. doi: 10.1016/j.lungcan.2015.04.004. Epub 2015 Apr 22. Lung Cancer. 2015. PMID: 25982012 Free PMC article.
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.
Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Tang C, et al. Among authors: subbiah v. Clin Cancer Res. 2017 Mar 15;23(6):1388-1396. doi: 10.1158/1078-0432.CCR-16-1432. Epub 2016 Sep 20. Clin Cancer Res. 2017. PMID: 27649551 Free PMC article. Clinical Trial.
Towards precision oncology in RET-aberrant cancers.
Subbiah V, Roszik J. Subbiah V, et al. Cell Cycle. 2017 May 3;16(9):813-814. doi: 10.1080/15384101.2017.1302235. Epub 2017 Mar 20. Cell Cycle. 2017. PMID: 28318386 Free PMC article. No abstract available.
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Subbiah V, et al. J Clin Oncol. 2018 Jan 1;36(1):7-13. doi: 10.1200/JCO.2017.73.6785. Epub 2017 Oct 26. J Clin Oncol. 2018. PMID: 29072975 Free PMC article. Clinical Trial.
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.
Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F. Sakamuri D, et al. Among authors: subbiah v. Mol Cancer Ther. 2018 Mar;17(3):671-676. doi: 10.1158/1535-7163.MCT-17-0673. Epub 2017 Dec 13. Mol Cancer Ther. 2018. PMID: 29237802 Free PMC article. Clinical Trial.
604 results